Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Scales Up Remdesivir Production To Meet Indian Demand

Company Donates 450,000 Vials For Immediate Need

Executive Summary

To tackle the increase in demand for remdesivir in India amidst the second wave of COVID-19, Gilead Sciences is helping local licensees to scale up production of the product, including by providing API supplies. The company is also donating at least 450,000 vials of the Veklury brand “to help address the immediate needs of Indian patients.”

You may also be interested in...



IPA’s Jain Predicts 3-4 Weeks To Meet Indian Shortages

Speaking exclusively to Generics Bulletin, Indian Pharmaceutical Alliance secretary general Sudarshan Jain says that India’s needs for COVID drugs like favipiravir, remdesivir and tocilizumab will be met “in the near future.” Current IGBA chair Jain also talks about global collaboration by governments and donors for equal vaccine distribution through the Access to COVID-19 Tools Accelerator.

Dr Reddy’s Joins Remdesivir Licensees

Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.

Gilead Licenses Remdesivir To Five Firms

Gilead has announced a raft of licensing agreements with five generics firms to manufacture potential COVID-19 treatment remdesivir for distribution in 127 countries.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel